These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 18519662)

  • 1. Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12.
    Zheng R; Cohen PA; Paustian CA; Johnson TD; Lee WT; Shu S; Koski GK
    Cancer Res; 2008 Jun; 68(11):4045-9. PubMed ID: 18519662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines.
    Cho EI; Tan C; Koski GK; Cohen PA; Shu S; Lee WT
    Head Neck; 2010 Jun; 32(6):700-7. PubMed ID: 19908319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination.
    Tan C; Dannull J; Nair SK; Ding E; Tyler DS; Pruitt SK; Lee WT
    J Surg Res; 2013 Dec; 185(2):904-11. PubMed ID: 23891424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression.
    Jeon D; McNeel DG
    Oncoimmunology; 2022; 11(1):2054758. PubMed ID: 35340661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells.
    Tada H; Aiba S; Shibata K; Ohteki T; Takada H
    Infect Immun; 2005 Dec; 73(12):7967-76. PubMed ID: 16299289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics.
    Jarnicki AG; Conroy H; Brereton C; Donnelly G; Toomey D; Walsh K; Sweeney C; Leavy O; Fletcher J; Lavelle EC; Dunne P; Mills KH
    J Immunol; 2008 Mar; 180(6):3797-806. PubMed ID: 18322186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy.
    Jeon D; Hill E; Moseman JE; McNeel DG
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses.
    Loré K; Betts MR; Brenchley JM; Kuruppu J; Khojasteh S; Perfetto S; Roederer M; Seder RA; Koup RA
    J Immunol; 2003 Oct; 171(8):4320-8. PubMed ID: 14530357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TLR agonist combinations that stimulate Th type I polarizing responses from human neonates.
    Surendran N; Simmons A; Pichichero ME
    Innate Immun; 2018 May; 24(4):240-251. PubMed ID: 29673285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1-biased T-cell immunity.
    Kim WS; Kim H; Kwon KW; Im SH; Lee BR; Ha SJ; Shin SJ
    Oncotarget; 2016 Jun; 7(23):33765-82. PubMed ID: 27172902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toll-like receptor-mediated adjuvanticity and immunomodulation in dendritic cells: Implications for peptide vaccines.
    Mitchell D; Yong M; Raju J; Willemsen N; Black M; Trent A; Tirrell M; Olive C
    Hum Vaccin; 2011; 7 Suppl():85-93. PubMed ID: 21245658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.
    Moreno Ayala MA; Gottardo MF; Gori MS; Nicola Candia AJ; Caruso C; De Laurentiis A; Imsen M; Klein S; Bal de Kier Joffé E; Salamone G; Castro MG; Seilicovich A; Candolfi M
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1713-1732. PubMed ID: 28432455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination.
    Kuriyama H; Watanabe S; Kjaergaard J; Tamai H; Zheng R; Weinberg AD; Hu HM; Cohen PA; Plautz GE; Shu S
    Cell Immunol; 2006 Sep; 243(1):30-40. PubMed ID: 17207783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses.
    Dowling DJ; Scott EA; Scheid A; Bergelson I; Joshi S; Pietrasanta C; Brightman S; Sanchez-Schmitz G; Van Haren SD; Ninković J; Kats D; Guiducci C; de Titta A; Bonner DK; Hirosue S; Swartz MA; Hubbell JA; Levy O
    J Allergy Clin Immunol; 2017 Nov; 140(5):1339-1350. PubMed ID: 28343701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses.
    Zhang X; Munegowda MA; Yuan J; Wei Y; Xiang J
    J Leukoc Biol; 2010 Aug; 88(2):393-403. PubMed ID: 20466823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists.
    Roses RE; Xu S; Xu M; Koldovsky U; Koski G; Czerniecki BJ
    J Immunol; 2008 Oct; 181(7):5120-7. PubMed ID: 18802116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration.
    Boullart AC; Aarntzen EH; Verdijk P; Jacobs JF; Schuurhuis DH; Benitez-Ribas D; Schreibelt G; van de Rakt MW; Scharenborg NM; de Boer A; Kramer M; Figdor CG; Punt CJ; Adema GJ; de Vries IJ
    Cancer Immunol Immunother; 2008 Nov; 57(11):1589-97. PubMed ID: 18322684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells.
    Suzuki T; Fukuhara T; Tanaka M; Nakamura A; Akiyama K; Sakakibara T; Koinuma D; Kikuchi T; Tazawa R; Maemondo M; Hagiwara K; Saijo Y; Nukiwa T
    Clin Cancer Res; 2005 Jan; 11(1):58-66. PubMed ID: 15671528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential activation of dendritic cells by Toll-like receptor agonists isolated from the Gram-positive vaccine vector Streptococcus gordonii.
    Mayer ML; Phillips CM; Townsend RA; Halperin SA; Lee SF
    Scand J Immunol; 2009 Apr; 69(4):351-6. PubMed ID: 19284500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined TLR stimulation with Pam3Cys and Poly I: C enhances Flt3-ligand dendritic cell activation for tumor immunotherapy.
    Lim SN; Kuhn S; Hyde E; Ronchese F
    J Immunother; 2012; 35(9):670-9. PubMed ID: 23090076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.